MetaCap

Jaguar Health (JAGX) vs Mustang Bio (MBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Jaguar Health is the larger company by market cap ($3.0 million vs $2.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JAGX-95.46%MBIO-21.35%
+8%-46%-100%
Oct 7, 20261 yearNov 20, 2026
JAGX-95.26%MBIO-11.50%
+10%-45%-100%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JAGX versus MBIO key metrics
MetricJAGXMBIO
Share price$0.227$0.3541
Market cap$3.03M$2.69M
1-day change-30.58%-4.30%
EPS (TTM)$-257.15$-0.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$11.51M—
Revenue growth (YoY)-1.52%—
Net income (latest FY)$-53.58M$-1.92M
Gross margin67.21%—
Operating margin-398.82%—
Net margin-465.42%—
52-week high$981.75$1.43
52-week low$0.22$0.35
Distance from 52-week high-99.98%-75.24%
Average volume2.40M33.87K
Shares outstanding13.35M6.74M
Employees474
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Jaguar Health

JAGX stock →

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

About Mustang Bio

MBIO stock →

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

JAGX vs MBIO FAQ

Which is bigger, Jaguar Health or Mustang Bio?

Jaguar Health (JAGX) is larger, with a market capitalization of $3.03M compared with $2.69M for Mustang Bio (MBIO).

Are Jaguar Health and Mustang Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons